Arbutus Biopharma Stock Forum

$Arbutus Biopharma(ABUS.US)$ $Barinthus Biotherapeutics(BRNS.US)$ Arbutus Biopharma (ABUS) said Thursday data from a phase 2a trial in patients with chronic hepatitis B virus infection showed that treatment with imdusiran followed by Barinthus Biotherapeutics' (BRNS) VTP-300 was generally safe and well-tolerated.
Based on preliminary end-of-treatment data, Arbutus said that the therapy resulted in maintenance of lower hepatitis B surface antigen levels during the post-treatment follow-up period.
...

$Arbutus Biopharma(ABUS.US)$
Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
Arbutus Biopharma (Nasdaq: ABUS) has announced promising new data presented at the European Association for the Study of the Liver (EASL) Congress regarding its RNAi therapeutic, Imdusiran, combined with the T-cell stimulating immunotherapeutic VTP-300. The Phase 2a trial showed significant reductions in Hepatitis B surface antigen (HBsAg) levels. At 24-weeks ...

🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics(IOVA.US)$  Phase 2
$Supernus Pharmaceuticals(SUPN.US)$  Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US)$  Phase 2a
$MorphoSys(MOR.US)$  Phase 2
$Nuvation Bio(NUVB.US)$  Phase 2
$ALX Oncology(ALXO.US)$  Phase 2
$BioXcel Therapeutics(BTAI.US)$  Phase 2
$Purple Biotech(PPBT.US)$  Phase 2
$Arcus Biosciences(RCUS.US)$  Phase 2
$Medicenna Therapeutics(MDNAF.US)$  Phase 2b
$Affimed NV(AFMD.US)$  Phase 2
$Barinthus Biotherapeutics(BRNS.US)$  Phase 2b...

Gainers:
In reaction to earnings/guidance:
• $Super Micro Computer(SMCI.US)$ +18%, $Nokia Oyj(NOK.US)$ +7.7%, $Danaher(DHR.US)$ +6.3%, $RLI Corp(RLI.US)$ +5%, $CSX Corp(CSX.US)$ +4.3%, $Las Vegas Sands(LVS.US)$ +4.2%, $Alcoa(AA.US)$ +3.4%(also authorizes new $500 mln share repurchase program)
• $Steel Dynamics(STLD.US)$ +2.8%, $Herc Holdings(HRI.US)$ +2.6%, $Tesla(TSLA.US)$ +2.5%, $Philip Morris International(PM.US)$ +2.5%, $F.N.B. Corp(FNB.US)$ ...

$WiMi Hologram Cloud(WIMI.US)$Not leaving. Actually will buy some more!
$Nokia Oyj(NOK.US)$ $Arbutus Biopharma(ABUS.US)$

Gainer:
• $Red Robin(RRGB.US)$ +13.8% (In reaction to earnings)
• $PMV Pharmaceuticals(PMVP.US)$ +11.2% (ASCO-related announcement)
• $Sumo Logic(SUMO.US)$ +10.8% (In reaction to earnings)
• $Adicet Bio(ACET.US)$ +9.6% (ASCO-related announcement)
• $Dell Technologies(DELL.US)$ +9.6% (In reaction to earnings)
• $ImmunoGen(IMGN.US)$ +8.7% (ASCO-related announcement)
• $Ulta Beauty(ULTA.US)$ +7.9% (In reaction to earnings)
• $Zymergen(ZY.US)$ +7.8% (to...

The Court of Appeals for the Federal Circuit (CAFC) just issued it's Mandate in connection with $Moderna(MRNA.US)$'s unsuccessful appeal of the '069 patent's validity.  So the CAFC is now done with the case.  Good news for $Arbutus Biopharma(ABUS.US)$ .